N/A N=78 Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes
Idiopathic Macular Hole
Primary: Visual Acuity (ETDRS Letters) — 74.9; 72.4; 72.2 Visual acuity in letters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Effects of Pneumatic Vitreolysis on Macular Hole
Vitreomacular Traction (VMT) · Full-thickness Macular Holes (MH)
Primary: Proportion of Eyes With Macular Hole Closure of Inner Retinal Layers Without Rescue Vitrectomy — 10 Eyes
Phase 3 N=220 Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Vitreomacular Adhesion Including Macular Hole
Primary: Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28 — 41.7; 6.2 Percentage (weighted across…
N/A N=19 Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration
Macular Degeneration · Retinal Drusen
Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3
Phase 3 N=326 Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28 — 25.3; 6.2 percentage of participants — p=<0.001
Phase 3 N=172 A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
Symptomatic Vitreomacular Adhesion
Primary: Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA) — 52.2; 1.8 percentage of subjects
Phase 2 N=100 Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
Exudative Age-Related Macular Degeneration · Focal Vitreomacular Adhesion
Primary: Proportion of Subjects With Focal Vitreomacular Adhesion (VMA) Release by Day 28 — 24.3; 12.0 percentage of subjects — p=0.262
N/A N=36 A Multi-Center Study of Reading Rehabilitation in Macular Disease
Age Related Maculopathy · Retinal Degeneration
Primary: Sentence Reading — 58.9; 50.5; 86.2; 49.1 Words per Minute (wpm)
N/A N=33 Efficacy of Acupuncture in Macular Diseases
Age-related Macular Degeneration · Stargardt Disease · Macular Dystrophy
Primary: Change on Visual Acuity (VA) of the Treated Eyes From Baseline to the End of the Study — 36; 16; 4 Eyes
Phase 3 N=46 Effects of Pneumatic Vitreolysis on Vitreomacular Traction
Vitreomacular Traction
Primary: Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy — 78; 9 percentage of eyes
Phase 2 N=6 The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
Age Related Macular Degeneration
Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters
Phase 4 N=52 Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Vitreomacular Traction · Vitreomacular Adhesion
Primary: Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence…
Phase 4 N=30 Transfoveal Micropulse Laser for Center Involving Diabetic Macular Edema
Diabetic Retinopathy · Macula Edema
Primary: Change in Central Retinal Thickness (CRT) — 384.62; 374; 349.15; 357.62 micrometer
Phase 4 N=44 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
Phase 4 N=81 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Macular Degeneration
Primary: Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) — 40; 7; 33 participants
N/A N=38 Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification
Posterior Capsule Opacification · Retinal Degeneration · Retinal Detachment
Primary: Changes of Foveal and Pericentral Pigment Optical Density (Log Unit) From Baseline at 2 Months — 0.55; 0.52; 0.51; 0.5 log unit — p=<0.01
N/A N=27 Micropulse for Suppression of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76
Phase 3 N=120 A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
Macular Telangiectasia Type 2 (MacTel)
Primary: The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24 — 0.075; 0.166 mm^2 — p=<0.0001
N/A N=87 Evaluation of Vitrectomy for Diabetic Macular Edema
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Visual Acuity — 52 Units on a scale
N/A N=52 Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)
Age Related Macular Degeneration · Geographic Atrophy
Primary: Difference in mm Squared of Cirrus HD-OCT Automated Measurements of the Illumination Areaa Under the RPE to Expert Manual Measurement of Areas of Hypofluorescence…
N/A N=9 Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects
Low Vision · Age Related Macular Degeneration
Primary: Tilt of the PCIOL and IOPCL MAG Complex — 9; 9 Eyes
N/A N=26 Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related Macular Degeneration
Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05
Phase 3 N=326 Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28. — 27.9; 13.1 percentage of participants — p=0.003
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 2 N=20 Diabetic Macular Edema Treated With Ozurdex (DMEO)
Diabetic Macular Edema
Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…
Phase 3 N=119 A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
Macular Telangiectasia Type 2
Primary: The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24 — 0.111; 0.160 mm^2 — p=0.0186
Phase 2 N=49 Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
Exudative Age-Related Macular Degeneration
Primary: Mean Reduction From Baseline in Central Subfield (CSF) Retinal Thickness at Week 4 — 514.2; 551.8; -12.1; 199.9 microns
N/A N=20 Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD
Age-Related Macular Degeneration · Geographic Atrophy · Reticular Pseudodrusen
Primary: Retinal Sensitivity — 12.08; 11.08; 11.45 dB — p=0.404
Phase 2 N=320 A Study of NGM621 in Participants With Geographic Atrophy
Geographic Atrophy
Primary: The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area — 2.243; 2.237; 2.393 mm^2 per year — p=0.4345
Phase 4 N=46 Study for Recalcitrant Age Related Macular Degeneration
Age Related Macular Degeneration
Primary: The Number of Patients With no Fluid on OCT — 10 participants